Beyond NMDA Receptors: A Narrative Review of Ketamine’s Rapid and Multifaceted Mechanisms in Depression Treatment DOI Open Access

Z Antoś,

Xawery Żukow,

Laura Bursztynowicz

и другие.

International Journal of Molecular Sciences, Год журнала: 2024, Номер 25(24), С. 13658 - 13658

Опубликована: Дек. 20, 2024

The rising prevalence of depression, with its associated suicide risk, demands effective fast-acting treatments. Ketamine has emerged as promising, demonstrating rapid antidepressant effects. While early studies show swift mood improvements, precise mechanisms remain unclear. This article aims to compile and synthesize the literature on ketamine's molecular actions. primarily works by antagonizing NMDA receptors, reducing GABAergic inhibition, increasing glutamate release. enhanced activates AMPA triggering crucial downstream cascades, including BDNF-TrkB mTOR pathways, promoting synaptic proliferation regeneration. Moreover, neuroimaging have demonstrated alterations in brain networks involved emotional regulation, Default Mode Network (DMN), Central Executive (CEN), Salience (SN), which are frequently disrupted depression. Despite promising findings, reveals significant inaccuracies gaps understanding full scope therapeutic potential. For instance, ketamine engages opioid insinuating a permissive role system amplifying effects, albeit does not operate direct agonist. Further exploration is requisite comprehensively ascertain safety profile, long-term efficacy, impact genetic determinants, such BDNF polymorphisms, treatment responsiveness.

Язык: Английский

Ketamine: Therapeutic potential versus recreational misuse DOI
Mário F. Juruena, Allan H. Young

Journal of Psychopharmacology, Год журнала: 2025, Номер 39(1), С. 3 - 4

Опубликована: Янв. 1, 2025

Язык: Английский

Процитировано

0
Ketamine-Occasioned Mystical Experience in Veterans with Treatment-Resistant Depression: A Retrospective Exploratory Analysis DOI
Kush V. Bhatt,

Jason Compton,

Em Ellerman

и другие.

Psychedelic Medicine, Год журнала: 2025, Номер unknown

Опубликована: Апрель 24, 2025

Язык: Английский

Процитировано

0
Psychiatric Care, Training and Research in Aotearoa New Zealand DOI Creative Commons
Chao‐Cheng Lin, Charlotte Mentzel,

Maria Luz C. Querubin

и другие.

Taiwanese Journal of Psychiatry, Год журнала: 2024, Номер 38(4), С. 161 - 170

Опубликована: Окт. 1, 2024

Abstract Objective: Aotearoa New Zealand, a commonwealth country, is situated in the South Pacific Ocean, southwestern most part of Polynesia. The country comprises two main islands – North and Islands with total population 5 million. Within this context, authors describe mental health (including indigenous Māori perspective), psychiatrist training, healthcare system, recent research Zealand. This review intended to familiarize readers Taiwanese Journal Psychiatry current status psychiatric practice Methods: collected reviewed relevant literature on care, education, In addition, official government publications, such as reports from Stats Zealand Ministry Health, were examined gather data. Results: After providing brief overview Zealand’s geography history, major ethnic groups, Zealanders European descents, Māori, who are descendants Polynesian settlers. Then, prevalence diseases, trainings for workforce, Royal Australian College Psychiatrists, Mental Health Act, highlighted. Conclusion: dominant cultural groups an emerging Asian population, has growing, diverse population. Its universal restructured 2022 under Te Whatu Ora (Health Zealand) aimed at enhancing efficiency equity but faces challenges like underrepresentation psychiatry workforce rising demands growing community. While issues have gained attention, future advancements needed improve recruitment retention, enhance equitable service delivery, strengthen laws, increase funding.

Язык: Английский

Процитировано

1
EFICÁCIA DA CETAMINA EM PACIENTES COM TRANSTORNO DEPRESSIVO MAIOR RESISTENTE AO TRATAMENTO: UMA REVISÃO INTEGRATIVA DOI Open Access

Ana Carolina Souza Ameno,

Maria Clara Antoniassi Caron,

Ana Luiza Gonçalves Campos

и другие.

Revista CPAQV - Centro de Pesquisas Avançadas em Qualidade de Vida, Год журнала: 2024, Номер 16(2)

Опубликована: Май 30, 2024

A depressão resistente ao tratamento (DRT) é uma condição psiquiátrica definida pela falta de remissão suficiente dos sintomas depressivos após, no mínimo, duas tentativas antidepressivo com doses e duração adequadas, estimativas prevalência que variam forma significativa, valores entre 12 a 55%, o ocorre critérios consistentes usados para sua determinação. O presente estudo revisão buscou avaliar novos estudos acerca da eficácia segurança cetamina em pacientes tratamento, partir ensaios clínicos publicados na literatura médica atual. Trata-se pesquisa integrativa, levou consideração os seguintes inclusão: artigos texto completo disponível, randomizados, último ano (2023-2024), nos idiomas inglês, português ou espanhol abordassem do uso transtorno depressivo maior tratamento. Ficou constatado administração intravenosa demonstrou significativa comparação placebos tratamentos convencionais, proporcionando alívio imediato se mantém por semanas após administração. Além disso, racêmica administrada via subcutânea também apresentou resultados encorajadores, taxas superiores às comparativos, como midazolam, ressalta viabilidade dessa alternativa eficaz segura contínuo DRT.

Процитировано

0
Navigating the challenge of patient selection and scales to measure outcomes in ketamine trials for treatment-resistant depression DOI

Sarah Pereira Gomes,

Sofia Rodrigues Lima,

Fábio Gomes de Matos e Souza

и другие.

Journal of Psychopharmacology, Год журнала: 2024, Номер unknown

Опубликована: Сен. 12, 2024

The letter about the article “Ketamine for treatment-resistant major depressive disorder: Double-blind active-controlled crossover study” that discusses some points methodology, outcome measures, and results.

Язык: Английский

Процитировано

0
Plasminogen Activator Inhibitor‐1 in the Pathophysiology of Late Life Depression DOI
Lucie Métivier, Denis Vivien,

R. Goy

и другие.

International Journal of Geriatric Psychiatry, Год журнала: 2024, Номер 39(11)

Опубликована: Ноя. 1, 2024

ABSTRACT Introduction Late life depression (LLD) is characterized by specific clinical features including a high frequency of vascular form and frequent antidepressant treatment resistance. The expression functions the serine protease inhibitor, Plasminogen Activator Inhibitor‐1 (PAI‐1) known to be altered aging, damage, insulin levels associated with sedentary lifestyle, chronic stress leading hypercortisolemia, inflammatory changes linked responses. These phenomena would implicated in LLD like depression. This article thus aims review existing literature regarding association between plasmatic PAI‐1, marker hypofibrinolysis. We hypothesize that increased age PAI‐1 plasma level function which influence pathogenesis its treatment. Results Although large number studies on elderly exist, about implications are sparse. Despite heterogeneous findings direction variation among participants LLD, all demonstrated an current or remitted depressive symptoms. Moreover, disruptions concentrations other biological markers influencing expression, such as cytokines adipokines, were also observed, notably increase interleukins 6 8. Discussion genesis appears influenced regulatory loops senescence cell death. resistance distinct profiles involving fibrinolytic factors. Taken together these data suggest pathway may promising target development efforts for general.

Язык: Английский

Процитировано

0
Ketamine for treatment-resistant obsessive-compulsive disorder: Double-blind active-controlled crossover study DOI
Ben Beaglehole, Paul Glue,

Shona Neehoff

и другие.

Journal of Psychopharmacology, Год журнала: 2024, Номер unknown

Опубликована: Ноя. 28, 2024

Background: Obsessive-Compulsive Disorder (OCD) may respond to ketamine treatment. Aim: To examine the responsiveness and tolerability of treatment-refractory OCD intramuscular (IM) compared IM fentanyl. Methods: This was a randomised double-blind psychoactive-controlled study with single doses racemic 0.5 mg/kg, 1.0 mg/kg or fentanyl 50 µg (psychoactive control). Pre-dosing 4 mg oral ondansetron provided nausea prophylaxis. Eligible participants were aged between 18 years severe treatment-resistant OCD. The primary efficacy measure Yale-Brown Scale (Y-BOCS). Tolerability measured Clinician-Administered Dissociative States (CADSS). Repeated measures analysis variance orthogonal polynomial trends used assess effect drug treatment on Y-BOCS CADSS scores. Results: Twelve 10 completed (7 females, 3 males, mean age 33 years). Two dropped out due not tolerating dissociative effects associated medication. reductions in scores greater statistically dose-related for both than (dose [linear], F(1, 9) = 6.5, p 0.031). Score changes all treatments maximal at 1–2 h steady separation 168 h. Ketamine short-term cardiovascular effects. Conclusions: We provide further preliminary evidence an outpatient cohort Additional work is required establish optimal dosing regimen longer-term role These findings are encouraging given well-known limitations that exist this area.

Язык: Английский

Процитировано

0
Beyond NMDA Receptors: A Narrative Review of Ketamine’s Rapid and Multifaceted Mechanisms in Depression Treatment DOI Open Access

Z Antoś,

Xawery Żukow,

Laura Bursztynowicz

и другие.

International Journal of Molecular Sciences, Год журнала: 2024, Номер 25(24), С. 13658 - 13658

Опубликована: Дек. 20, 2024

The rising prevalence of depression, with its associated suicide risk, demands effective fast-acting treatments. Ketamine has emerged as promising, demonstrating rapid antidepressant effects. While early studies show swift mood improvements, precise mechanisms remain unclear. This article aims to compile and synthesize the literature on ketamine's molecular actions. primarily works by antagonizing NMDA receptors, reducing GABAergic inhibition, increasing glutamate release. enhanced activates AMPA triggering crucial downstream cascades, including BDNF-TrkB mTOR pathways, promoting synaptic proliferation regeneration. Moreover, neuroimaging have demonstrated alterations in brain networks involved emotional regulation, Default Mode Network (DMN), Central Executive (CEN), Salience (SN), which are frequently disrupted depression. Despite promising findings, reveals significant inaccuracies gaps understanding full scope therapeutic potential. For instance, ketamine engages opioid insinuating a permissive role system amplifying effects, albeit does not operate direct agonist. Further exploration is requisite comprehensively ascertain safety profile, long-term efficacy, impact genetic determinants, such BDNF polymorphisms, treatment responsiveness.

Язык: Английский

Процитировано

0